These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 36466873)

  • 1. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
    Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
    Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of gut microbiota in regulating immune checkpoint inhibitor therapy for glioblastoma.
    Zhang H; Hong Y; Wu T; Ben E; Li S; Hu L; Xie T
    Front Immunol; 2024; 15():1401967. PubMed ID: 38915399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.
    Habashy KJ; Mansour R; Moussalem C; Sawaya R; Massaad MJ
    Br J Cancer; 2022 Oct; 127(6):976-987. PubMed ID: 35662275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
    Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
    Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 11. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.
    Huang B; Zhang J; Zong W; Chen S; Zong Z; Zeng X; Zhang H
    Front Immunol; 2023; 14():994698. PubMed ID: 36923402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
    Front Immunol; ; . PubMed ID: 33117364
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.